Net loss of Biocon reported to Rs 16.00 crore in the quarter ended September 2024 as against net profit of Rs 125.60 crore during the previous quarter ended September 2023. Sales rose 4.49% to Rs 3545.00 crore in the quarter ended September 2024 as against Rs 3392.60 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales3545.003392.60 4 OPM %19.3321.15 - PBDT492.30627.60 -22 PBT72.40238.30 -70 NP-16.00125.60 PL Powered by Capital Market - Live News

Biocon will hold a meeting of the Board of Directors of the Company on 30 October 2024.Powered by Capital Market - Live News

Biocon Biologics (BBL), a subsidiary of Biocon, today announced the successful pricing of Biocon Biologics` debut USD 800 million (Rs 6676.3 crore) senior secured Notes due 2029 at a coupon of 6.67%. The Bonds will be issued by Biocon Biologics Global plc which is a wholly owned subsidiary of BBL and will be backed by a strong security package. The Bonds are expected to be rated BB by both S&P and Fitch and will be listed on the Singapore Stock Exchange. The transaction is expected to settle on October 09, 2024 subject to customary closing conditions.Additionally, Biocon Biologics has entered into a commitment agreement for a new syndicated debt facility. The proceeds of the Bonds, together with the new syndicated debt facility being raised, will be used to substantially re-finance existing debt of USD 1.1 billion (Rs 9346.8 crore) which will help improve the Company`s liquidity profile, provide financial flexibility and opportunity to re-invest the cash into the business.Powered by Capital Market - Live News

Biocon announced the signing of a licensing and supply agreement with Tabuk Pharmaceutical Manufacturing Company (a fully-owned subsidiary of Astra Industrial Group), a leading pharmaceutical company in the Middle East and North Africa (MENA) region, to commercialize its GLP-1 products for treating diabetes and chronic weight management, in select countries of the Middle East. Under the terms of this agreement, Biocon will develop and manufacture the products and Tabuk Pharmaceuticals will hold the marketing authorization rights, and be responsible to register, import, and promote them in the region. The agreement also provides for a provision to expand to other GLP products, as well as the option of a tech transfer that will enable localized manufacturing at a later stage.Powered by Capital Market - Live News

Net profit of Biocon rose 550.59% to Rs 659.70 crore in the quarter ended June 2024 as against Rs 101.40 crore during the previous quarter ended June 2023. Sales rose 0.30% to Rs 3432.90 crore in the quarter ended June 2024 as against Rs 3422.60 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales3432.903422.60 0 OPM %18.0719.90 - PBDT1518.90541.70 180 PBT1113.50183.70 506 NP659.70101.40 551 Powered by Capital Market - Live News